

**ASX Announcement: 20 May 2026 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX: OIL)**

OPTISCAN RECEIVES \$1.69M R&D TAX REFUND

Optiscan Imaging Limited (ASX:OIL) ('Optiscan' or the 'Company'), a leader in medical imaging using confocal laser endomicroscopy, is pleased to advise that it has received its FY25 research and development (R&D) tax refund of \$1,693,714. The refund forms part of the Australian Federal Government's R&D tax incentive program, which provides eligible companies undertaking qualifying R&D activities with a refundable tax offset of up to 43.5%.

The FY25 refund compares with \$1,775,733 received in FY24 and is in line with the Company's expectations. Importantly, the FY25 outcome remains elevated relative to prior years, reflecting the successful Advance and Overseas Finding application secured in FY24, which enables eligible overseas R&D expenditure to be claimed under the Australian Government's R&D tax incentive program.

CEO COMMENT

Optiscan CEO and Managing Director, Dr Camile Farah, said:

"The Australian Government's R&D tax incentive continues to provide valuable support for Optiscan's innovation pipeline and clinical development activities. This FY25 refund reinforces our funding position and supports continued investment in key R&D programs and clinical studies as we progress toward broader commercialisation of our technology. We welcome the ongoing support of initiatives that help Australian innovators translate globally relevant medical technologies into meaningful clinical and shareholder value."

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.